17 unknown, 12 recruiting, 8 active not recruiting, 8 completed. 60 Phase 2, 8 Phase 1.
Follow NSCLC Stage IV: new trials by email Literature Review of NSCLC Stage IV trials Research Report on NSCLC Stage IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC Glecirasib, Ivonescimab - NSCLC Stage IV, KRAS G12C | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 42 | 2026-03-01 | 2026-01-14 |
| A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy sacituzumab tirumotecan - NSCLC Stage IV, EGFR Gene Mutation | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 25 | 2026-02-01 | 2026-04-23 |
| Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg Firmonertinib 160mg - NSCLC Stage IV, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 28 | 2026-01-01 | 2026-01-21 |
| Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab - NSCLC Stage IV, Brain Metastases, Adult | Phase 2 | Recruiting | Maastricht University Medical Center | 25 | 2025-04-24 | 2025-05-06 |
| Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC Cemiplimab, Placebo - NSCLC Stage IV | Phase 2 | Active not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 136 | 2025-01-14 | 2026-06-23 |
| A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) Cabozantinib, Atezolizumab - Lung Cancer, NSCLC Stage IV | Phase 2 | Not yet recruiting | Jun Zhang, MD, PhD | 40 | 2024-12-01 | 2024-05-08 |
| Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC Repotrectinib - NSCLC Stage IV, NSCLC, Stage III | Phase 2 | Recruiting | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer | 30 | 2024-10-01 | 2026-07-07 |
| Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis PD-L1/PD-1 inhibitor and chemotherapy, SRT or WBRT - NSCLC Stage IV, Brain Metastases | Phase 2 | Recruiting | Fudan University | 54 | 2024-07-01 | 2024-08-28 |
| Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis PD-1/PD-L1 inhibitor plus chemotherapy, SRT/WBRT - NSCLC Stage IV | Phase 2 | Completed | Fudan University | 40 | 2024-07-01 | 2026-09-14 |
| Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC Peptide vaccine - NSCLC Stage IV, ALK Fusion Protein Expression | Phase 1 / Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 12 | 2024-05-13 | 2026-07-28 |
| Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy SBRT or LDRT, PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy - NSCLC Stage IV | Phase 2 | Unknown | Fudan University | 146 | 2024-04-10 | 2024-06-05 |
| A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients HLX26, Serplulimab, Chemotherapy drug - NSCLC Stage IV | Phase 2 | Active not recruiting | Shanghai Henlius Biotech | 132 | 2023-07-10 | 2025-08-06 |
| Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status Adagrasib - NSCLC Stage IV, KRAS P.G12C | Phase 2 | Active not recruiting | ETOP IBCSG Partners Foundation | 68 | 2023-06-12 | 2026-09-03 |
| A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC YH001 + Toripalimab - HCC, NSCLC Stage IIIB | Phase 2 | Withdrawn | Eucure (Beijing) Biopharma Co., Ltd | 2023-06-01 | 2023-03-20 | |
| Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) Cadonilimab, Anlotinib, Docetaxel - NSCLC Stage IV, NSCLC Stage IIIB | Phase 1 / Phase 2 | Unknown | Shanghai Chest Hospital | 50 | 2023-02-16 | 2024-06-17 |
| Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome Nivolumab and Ipilimumab - NSCLC Stage IV, HIV | Phase 2 | Not yet recruiting | Universita di Verona | 105 | 2023-02-01 | 2022-10-28 |
| Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC Pembrolizumab, Radiation, Chemotherapy - NSCLC Stage IV | Phase 2 | Terminated | NYU Langone Health | 19 | 2023-01-24 | 2025-07-29 |
| A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) L-SABR, Anti-PD-(L)1 based immunotherapy, Platinum based chemotherapy - Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 68 | 2022-12-09 | 2026-05-07 |
| A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC M701 pleural infusion, Pleural drainage, Cisplatin pleural infusion - Malignant Pleural Effusions, NSCLC Stage IV | Phase 1 / Phase 2 | Recruiting | Wuhan YZY Biopharma Co., Ltd. | 116 | 2022-09-30 | 2026-07-08 |
| Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer UV1, Sagramostim, Anti-PD-1/PD-L1 treatment - Oncology, NSCLC Stage IV | Phase 2 | Recruiting | Vestre Viken Hospital Trust | 138 | 2022-08-12 | 2023-11-09 |
Showing 20 of 60. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (60) · Lung Neoplasms (7) · Brain Neoplasms (5) · Adenocarcinoma of Lung (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Recurrence (2) · Melanoma (1) · Neoplasm, Residual (1) · Pleural Effusion, Malignant (1) · Post-Acute COVID-19 Syndrome (1) · Triple Negative Breast Neoplasms (1)
Bronchial Neoplasms (60) · Carcinoma, Bronchogenic (60) · Lung Diseases (60) · Neoplasms by Site (60) · Respiratory Tract Diseases (60) · Respiratory Tract Neoplasms (60) · Thoracic Neoplasms (60) · Neoplasms (58) · Lung Neoplasms (53) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Brain Diseases (5) · Central Nervous System Diseases (5) · Central Nervous System Neoplasms (5) · Nervous System Diseases (5)
Carboplatin (8) · Pemetrexed (8) · atezolizumab (6) · Drug Therapy (5) · Bevacizumab (4) · Platinum Compounds (4) · Radiosurgery (4) · pembrolizumab (4) · anlotinib (3) · camrelizumab (3) · osimertinib (3) · toripalimab (3) · Docetaxel (2) · L19-IL2 immunocytokine (2) · Nivolumab (2)
Fudan University (7) · Memorial Sloan Kettering Cancer Center (3) · ETOP IBCSG Partners Foundation (2) · Fujian Cancer Hospital (2) · Jun Zhang, MD, PhD (2) · Maastricht University Medical Center (2) · Shanghai Chest Hospital (2) · Vestre Viken Hospital Trust (2) · Zhejiang Cancer Hospital (2) · AIO-Studien-gGmbH (1) · Agenus Inc. (1) · Alethia Biotherapeutics (1) · BerGenBio ASA (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Centre Francois Baclesse (1)
China (24) · United States (12) · France (5) · Italy (5) · Netherlands (5) · Spain (5) · Germany (4) · Belgium (3) · Norway (3) · Switzerland (3) · United Kingdom (3) · Australia (2) · Canada (2) · Hong Kong (2) · Singapore (2)
Zhengfei Zhu, MD (3) · Jun Zhang, MD, PhD (2) · Odd Terje Brustugun, MD, PhD (2) · Philippe Lambin, MD, PhD (2) · Baohui Han, M.D (1) · Chao Huang, MD (1) · Daniel Gomez, MD (1) · Daniel Tan, BSc, MBBS, PhD (1) · Dirk de Ruysscher, MD (1) · Francesco Martucci, MD (1) · Frank Aboubakar Nana, MD (1) · Guy Ben-Betzalel, MD (1) · Jarushka Naidoo (1) · Jianjun Zou, MD, PhD (1)
PMID 32539805, PMID 33688020, PMID 34526044, PMID 34903471, PMID 35492873, PMID 36801605, PMID 38104577, PMID 38830303, PMID 38862908, PMID 39398493, PMID 39751937, PMID 39756446, PMID 40898159
2016 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1)